David N. Assis, MD

• Allen Bale
• Ariel Jaffe
• Carol Soroka
• Cary Caldwell
• Dennis Shung
• Dhanpat Jain
• Guadalupe Garcia-Tsao
• Hongyu Zhao
• James Boyer
• Jeffrey Pollak
• Jenn Batisti
• Joseph Lim
• Julius Chapiro
• Kisha A Mitchell
• Lin Leng
• Maor Sauler
• Maria Ciarleglio
• Marina Silveira
• Michael Schilsky
• Pramod Mistry
• Richard Bucala
• Roberto Groszmann
• Sanjay Kulkarni
• Sarah Taylor
• Shi-Ying Cai
• Silvia Vilarinho
• Tamar Taddei
• Wajih Kidwai
• Xuchen Zhang
• Yanhong Deng

Autoimmune Diseases; Cystic Fibrosis; Hepatitis; Liver; Liver Diseases

Hepatitis

• The role of macrophage migration inhibitory factor in autoimmune liver disease.Assis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, Garcia AB, McCrann C, Chapiro J, Meinhardt A, Mizue Y, Nikolic-Paterson DJ, Bernhagen J, Kaplan MM, Zhao H, Boyer JL, Bucala R. The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology (Baltimore, Md.) 2014, 59:580-91.
• A Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Autoimmune Hepatitis Severity in US and Japanese Patients.Assis DN, Takahashi H, Leng L, Zeniya M, Boyer JL, Bucala R. A Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Autoimmune Hepatitis Severity in US and Japanese Patients. Digestive Diseases And Sciences 2016, 61:3506-3512.
• Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.Assis DN, Abdelghany O, Cai SY, Gossard AA, Eaton JE, Keach JC, Deng Y, Setchell KD, Ciarleglio M, Lindor KD, Boyer JL. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study. Journal Of Clinical Gastroenterology 2017, 51:e11-e16.
• Gastrointestinal Disorders in Cystic Fibrosis.Assis DN, Freedman SD. Gastrointestinal Disorders in Cystic Fibrosis. Clinics In Chest Medicine 2016, 37:109-18.
• Editorial: environmental risk factors for PSC with and without IBD--the story unfolds.Assis DN, Levy C. Editorial: environmental risk factors for PSC with and without IBD--the story unfolds. Alimentary Pharmacology & Therapeutics 2015, 41:1214-6.
• Fibrates and cholestasis.Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology (Baltimore, Md.) 2015, 62:635-43.
• Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones.Mylin LM, Schell TD, Epler M, Kusuma C, Assis D, Matsko C, Smith A, Allebach A, Tevethia SS. Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones. Virology 2007, 364:155-68.
• Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations.Rossi S, Assis DN, Awsare M, Brunner M, Skole K, Rai J, Andrel J, Herrine SK, Reddy RK, Navarro VJ. Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations. Drug Safety 2008, 31:261-70.
• Dilated cisternae chyli: a sign of uncompensated cirrhosis at MR imaging.Verma SK, Mitchell DG, Bergin D, Lakhman Y, Austin A, Verma M, Assis D, Herrine SK, Parker L. Dilated cisternae chyli: a sign of uncompensated cirrhosis at MR imaging. Abdominal Imaging 2009, 34:211-6.
• Post-sphincterotomy transampullary balloon dilation is a safe and effective technique.Kowalski T, Nathwani RA, Assis D, Salese L, Banwait K, Loren D. Post-sphincterotomy transampullary balloon dilation is a safe and effective technique. Digestive Diseases And Sciences 2009, 54:670-4.
• Human drug hepatotoxicity: a contemporary clinical perspective.Assis DN, Navarro VJ. Human drug hepatotoxicity: a contemporary clinical perspective. Expert Opinion On Drug Metabolism & Toxicology 2009, 5:463-73.
• Testing and management of thrombocytopenia and coagulopathy in the pre- and postliver transplant patient.Assis DN, Schilsky ML. Testing and management of thrombocytopenia and coagulopathy in the pre- and postliver transplant patient. Minerva Gastroenterologica E Dietologica 2010, 56:331-43.
• Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.Cimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, Emre S. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation. Transplantation Proceedings 2011, 43:905-8.
• Successful treatment of a bleeding umbilical varix by percutaneous umbilical vein embolization with sclerotherapy.Assis DN, Pollak J, Schilsky ML, Emre S. Successful treatment of a bleeding umbilical varix by percutaneous umbilical vein embolization with sclerotherapy. Journal Of Clinical Gastroenterology 2012, 46:115-8.
• New pharmacotherapy for hepatitis C.Assis DN, Lim JK. New pharmacotherapy for hepatitis C. Clinical Pharmacology And Therapeutics 2012, 92:294-305.
• Now you see it, now you don’t.Plotkin E, Assis DN, Boyer JL. Hepatology. 2013;58:446-447 (Case Report)
• The interpretation of hepatic venous pressure gradient tracings - excellent interobserver agreement unrelated to experience.Tandon P, Ripoll C, Assis D, Wongcharatrawee S, Groszmann RJ, Garcia-Tsao G. The interpretation of hepatic venous pressure gradient tracings - excellent interobserver agreement unrelated to experience. Liver International : Official Journal Of The International Association For The Study Of The Liver 2016, 36:1160-6.
• The clinical significance of the MIF homolog d-dopachrome tautomerase (MIF-2) and its circulating receptor (sCD74) in burn.Kim BS, Stoppe C, Grieb G, Leng L, Sauler M, Assis D, Simons D, Boecker AH, Schulte W, Piecychna M, Hager S, Bernhagen J, Pallua N, Bucala R. The clinical significance of the MIF homolog d-dopachrome tautomerase (MIF-2) and its circulating receptor (sCD74) in burn. Burns : Journal Of The International Society For Burn Injuries 2016, 42:1265-76.
• Gallbladder and bile duct disease in Cystic Fibrosis.Assis DN, Debray D. Gallbladder and bile duct disease in Cystic Fibrosis. Journal Of Cystic Fibrosis : Official Journal Of The European Cystic Fibrosis Society 2017, 16 Suppl 2:S62-S69.
• Chapter 43: Primary and Secondary Sclerosing CholangitisBowlus CL, Assis DN, Goldberg DS. Zakim and Boyer’s Hepatology: A Textbook of Liver Disease. Elsevier (7th Edition).
• Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium.Goldberg D, Levy C, Yimam K, Gordon S, Forman L, Verna E, Yu L, Rahimi R, Schwarz K, Eksteen B, Pratt D, Boyer T, Assis D, Bowlus C. Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium. Clinical Gastroenterology And Hepatology : The Official Clinical Practice Journal Of The American Gastroenterological Association 2018, 16:591-593.
• Histologic features of autoimmune hepatitis: a critical appraisal.Gurung A, Assis DN, McCarty T, Mitchell KA, Boyer JL, Jain D. Histologic features of autoimmune hepatitis: a critical appraisal. Human Pathology 2018, 82:51-60.
• Chronic Complications of Cholestasis: Evaluation and Management.Assis DN. Chronic Complications of Cholestasis: Evaluation and Management. Clinics In Liver Disease 2018, 22:533-544.
• The Immunopathogenesis of Autoimmune HepatitisClinical Liver Disease (in press)
• Bile-Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune Profile.Soroka CJ, Assis DN, Alrabadi LS, Roberts S, Cusack L, Jaffe AB, Boyer JL. Bile-Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune Profile. Hepatology (Baltimore, Md.) 2019, 70:871-882.
• Clinical utility of genomic analysis in adults with idiopathic liver disease.Hakim A, Zhang X, DeLisle A, Oral EA, Dykas D, Drzewiecki K, Assis DN, Silveira M, Batisti J, Jain D, Bale A, Mistry PK, Vilarinho S. Clinical utility of genomic analysis in adults with idiopathic liver disease. Journal Of Hepatology 2019, 70:1214-1221.
• Patient-Derived Organoids from Human Bile: An In Vitro Method to Study Cholangiopathies.Soroka CJ, Assis DN, Boyer JL. Patient-Derived Organoids from Human Bile: An In Vitro Method to Study Cholangiopathies. Methods In Molecular Biology (Clifton, N.J.) 2019, 1981:363-372.
• The Contribution of B Cells in Autoimmune Liver Diseases.Taylor SA, Assis DN, Mack CL. The Contribution of B Cells in Autoimmune Liver Diseases. Seminars In Liver Disease 2019, 39:422-431.
• Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, Janneke van der Woude C, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK, Levy C. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clinical Gastroenterology And Hepatology : The Official Clinical Practice Journal Of The American Gastroenterological Association 2020, 18:179-187.e6.
• Machine Learning in a Complex Disease: PREsTo Improves the Prognostication of Primary Sclerosing Cholangitis.Shung DL, Assis DN. Machine Learning in a Complex Disease: PREsTo Improves the Prognostication of Primary Sclerosing Cholangitis. Hepatology (Baltimore, Md.) 2020, 71:8-10.
• Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases.Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.) 2020, 72:671-722.
• Immunopathogenesis of Autoimmune Hepatitis.Assis DN. Immunopathogenesis of Autoimmune Hepatitis. Clinical Liver Disease 2020, 15:129-132.
• Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol.Ghonem NS, Auclair AM, Hemme CL, Gallucci GM, de la Rosa Rodriguez R, Boyer JL, Assis DN. Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol. Clinical Pharmacology And Therapeutics 2020, 108:1213-1223.
• Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta-Analyses Supporting American Association for the Study of Liver Diseases Guidelines.Vierling JM, Kerkar N, Czaja AJ, Mack CL, Adams D, Assis D, Manns M, Mayo M, Nayfeh T, Majzoub AMM, Alzuabi MA, Ding J, Haffar S, Murad MH, Alsawas M. Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta-Analyses Supporting American Association for the Study of Liver Diseases Guidelines. Hepatology (Baltimore, Md.) 2020, 72:753-769.
• A Systematic Review of Patient-Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.Kim HP, Lieber SR, Rogers ME, Moon AM, Loiselle M, Walker J, Assis DN, Safer R, Gomel R, Evon DM. A Systematic Review of Patient-Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Hepatology Communications 2020, 4:1502-1515.
• Oral Vancomycin or Ursodeoxycholic Acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials.Assis DN, Levy C. Oral Vancomycin or Ursodeoxycholic Acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials. Hepatology (Baltimore, Md.) 2021, 73:887-889.
• Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study.Efe C, Dhanasekaran R, Lammert C, Ebi B, Higuera-de la Tijera F, Aloman C, Rıza Calışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM, Torgutalp M, Purnak T, Rigamonti C, Gomez Aldana AJ, Khakoo N, Kacmaz H, Nazal L, Frager S, Demir N, Irak K, Ellik ZM, Balaban Y, Atay K, Eren F, Cristoferi L, Batıbay E, Urzua Á, Snijders R, Kıyıcı M, Akyıldız M, Ekin N, Carr RM, Harputoğlu M, Hatemi I, Mendizabal M, Silva M, Idilman R, Silveira M, Drenth JPH, Assis DN, Björnsson E, Boyer JL, Invernizzi P, Levy C, Schiano TD, Ridruejo E, Wahlin S. Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. Hepatology (Baltimore, Md.) 2021, 73:2099-2109.
• Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report.Guercio BJ, Iyer G, Kidwai WZ, Lacouture ME, Ghafoor S, Rossi AM, Assis DN, Chen YB, Busam KJ, Janjigian YY, Jhaveri K, Feldman DR, Capozzi A, Figueroa V, Bajorin DF, Rosenberg JE, Hollmann TJ, Funt SA. Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. Case Reports In Oncology 2021, 14:430-438.
• Role of Biliary Organoids in Cholestasis Research and Regenerative Medicine.Soroka CJ, Roberts SJ, Boyer JL, Assis DN. Role of Biliary Organoids in Cholestasis Research and Regenerative Medicine. Seminars In Liver Disease 2021, 41:206-212.